PPTA Twitter

PlasmaProteins For individuals with #rarediseases --like primary immunodeficiency--timely diagnosis, access to specialists and #plasmaprotein therapies are life-saving. #ShowYourStripes bit.ly/2JFf1Db pic.twitter.com/fvO1nfG10q
1 day ago.
PlasmaProteins For Sam, access to #plasmaprotein therapies allows him to do more of what he loves, like playing in the school band. Read Sam's story: bit.ly/2yRIPJn pic.twitter.com/pECj0zihtw
3 days ago.

PPTA Responds to The Pharmaceutical Journal

In December 2017, The Pharmaceutical Journal published a correspondence piece that included a few misleading statements regarding the prospective use of gene therapy for treatment of common variable immune deficiency (CVID), when in reality, the treatment is only being discussed for a rare form of severe combined immunodeficiency caused by adenosine deaminase deficiency (SCID-ADA).

PPTA submitted a response to the original article with corrections to the original author's inaccuracies and misleading interpretations. The response article, "Keeping the record straight on the availability of gene therapy for common variable immunodeficiency," was published online last week.

plasma protein forum, , gene therapy, scid, cvid, pharmaceutical journal, immunodeficiency

Copyright © 2018 PPTA. All rights reserved. (202) 789-3100